Breaking News Instant updates and real-time market news.

BGFV

Big 5 Sporting

$3.11

0.005 (0.16%)

, ICHR

Ichor Holdings

$30.90

0.17 (0.55%)

19:00
01/13/20
01/13
19:00
01/13/20
19:00

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Big 5 Sporting Goods (BGFV) up 22.6%... Ichor Holdings (ICHR) up 14.6% after pre-announcing Q4 results... MagnaChip (MX) up 9.7% after raising Q4 guidance on better than expected OLED performance... The Container Store (TCS) up 5.8% after pre-announcing Q3 results... Limoneira (LMNR) up 4.1%... McKesson (MCK) up 3.4% after raising FY20 EPS guidance ahead of JP Morgan Heath Conference presentation. ALSO HIGHER: RTI Surgical (RTIX) up 97.5% after announcing sales of OEM business and guiding Q4 revenue above consensus... La Jolla (LJPC) up 10.7% after insider purchase... Zumiez (ZUMZ) up 7.9% after reporting holiday sales and raising Q4 guidance... Merit Medical (MMSI) up 7.9% after Starboard disclosed activist 9.0% stake... Wynn Resorts (WYNN) up 1.3% after being upgraded to Conviction Buy at Goldman Sachs. DOWN AFTER EARNINGS: ACI Worldwide (ACIW) down 10.5% after cutting FY19 guidance due to expired large contract... GameStop (GME) down 9.0% after reporting holiday sales and cutting FY19 SSS guidance... Ethan Allen (ETH) down 6.4% after negative Q2 pre-announcement. ALSO LOWER: Stemline Therapeutics (STML) down 20.5% after reporting preliminary Q4 Elzonris revenue... STAG Industrial (STAG) down 1.8% after equity offering. Movers as of 18:30ET.

BGFV

Big 5 Sporting

$3.11

0.005 (0.16%)

ICHR

Ichor Holdings

$30.90

0.17 (0.55%)

MX

MagnaChip

$12.58

0.43 (3.54%)

TCS

Container Store

$4.10

0.06 (1.49%)

LMNR

Limoneira

$19.21

0.9 (4.92%)

MCK

McKesson

$143.62

-0.27 (-0.19%)

RTIX

RTI Surgical

$2.76

0.1 (3.76%)

LJPC

La Jolla

$7.02

1.02 (17.00%)

ZUMZ

Zumiez

$33.02

-0.78 (-2.31%)

MMSI

Merit Medical

$34.66

-0.03 (-0.09%)

WYNN

Wynn Resorts

$147.23

4.22 (2.95%)

ACIW

ACI Worldwide

$39.08

0.58 (1.51%)

GME

GameStop

$5.44

0.005 (0.09%)

ETH

Ethan Allen

$17.86

0.25 (1.42%)

STML

Stemline

$9.42

-0.38 (-3.88%)

STAG

STAG Industrial

$31.98

0.26 (0.82%)

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 14

    Jan

  • 17

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 26

    Mar

  • 14

    Jan

BGFV Big 5 Sporting
$3.11

0.005 (0.16%)

ICHR Ichor Holdings
$30.90

0.17 (0.55%)

11/14/19
11/14/19
NO CHANGE

Ichor Holdings management to meet with DA Davidson
Meeting to be held in Portland, OR on November 14 hosted by DA Davidson.
10/24/19
DADA
10/24/19
UPGRADE
Target $34
DADA
Buy
Ichor Holdings upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Thomas Diffely upgraded Ichor Holdings (ICHR) to Buy from Neutral with a price target of $34, up from $25. The analyst says that at 11-times his expected forward earnings, the stock is attractively priced relative to its closest peer Ultra Clean Holdings' (UCTT) 14-times multiple. Diffely is also positive on Ichor Holdings taking share from ASML Holding (ASML) and Appliet Materials (AMAT) with added strong leverage exposure to the "eventual memory recovery".
11/06/19
RILY
11/06/19
NO CHANGE
Target $40
RILY
Buy
Ichor Holdings price target raised to $40 from $35 at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target on Ichor Holdings shares to $40 from $35 after the company reported "mixed" Q3 results but gave guidance that "was even further above" than he previewed, driven by share gains and strength in Foundry/Logic and EUV Litho. Ellis, who cites healthy organic revenue growth, a strong track record of leading customer share gain, and "proven M&A," keeps a Buy rating on Ichor shares.
11/06/19
NEED
11/06/19
NO CHANGE
Target $36
NEED
Buy
Ichor Holdings price target raised to $36 from $25 at Needham
Needham analyst N. Quinn Bolton raised his price target on Ichor Holdings to $36 and kept his Buy rating after its Q3 earnings beat and guidance for strong sequential growth in Q4. The analyst cites the company's expectations of foundry and logic momentum being sustaining into Q1, with signs of memory recovery driven by the combination of TSMC (TSM) strength, ASML (ASML) EUV demand.
MX MagnaChip
$12.58

0.43 (3.54%)

TCS Container Store
$4.10

0.06 (1.49%)

10/17/19
GSCO
10/17/19
UPGRADE
Target $5.25
GSCO
Neutral
Container Store upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Kate McShane upgraded Container Store to Neutral from Sell with a price target of $5.25, down from $7.00. Following the recent underperformance, the analyst sees less downside risk for Container Store shares. McShane continues to believe consensus 2019 estimates for the company carry risk, but she believes the current valuation prices this in. She does not see Container Store's trading multiples trending lower from here.
10/17/19
10/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Container Store (TCS) upgraded to Neutral from Sell at Goldman Sachs with analyst Kate McShane saying after the recent underperformance, the she sees less downside risk for Container Store shares. 2. Teva (TEVA) upgraded to Buy from Hold at Gabelli with analyst Kevin Kedra citing reports that the company had proposed to settle its opioid litigation by giving away $15B of free drugs. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at Cowen with analyst Vivien Azer saying with Truly continuing to drive "outsized growth," and with new formulations and a lemonade line-extension slated for next year, the brand will continue to transform Boston Beer's "growth algorithm" and offset continued softness in beer and cider. 4. Cirrus Logic (CRUS) upgraded to Equal Weight from Underweight at Barclays analyst Blayne Curtis saying he no longer sees a downside catalyst and risk to consensus estimates. 5. Autoliv (ALV) upgraded to In Line from Underperform at Evercore ISI with analyst Chris McNally citing seasonality, the company's upcoming Capital Markets Day and as he rolled forward his auto supplier targets to 2021. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/19
GSCO
07/11/19
INITIATION
Target $7
GSCO
Sell
Container Store initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Kate McShane started Container Store with a Sell rating and $7 price target. The company has a good degree of overlap with the mass channel, which continues to expand the home offering, says the analyst. Further, she points out that Container Store has some tougher compares to lap this year.
LMNR Limoneira
$19.21

0.9 (4.92%)

05/14/19
SPHN
05/14/19
DOWNGRADE
Target $18
SPHN
Equal Weight
Limoneira downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Ben Bienvenu downgraded Limoneira to Equal Weight from Overweight and lowered his price target for the shares to $18 from $25. While the company lowered its full year guidance, second half of 2019 expectations remain too aggressive to totally eliminate the risk of another guidance reduction later in the year, Bienvenu tells investors in a research note. The analyst expects Limoneira shares to trade off today given the magnitude of the Q2 miss and lack of visibility into the remainder of fiscal 2019.
05/14/19
LSCM
05/14/19
NO CHANGE
Target $28
LSCM
Buy
Limoneira results hurt by rains in Southern California, says Lake Street
Poor weather hurt Limoneira's lemon and orange businesses in the company's preliminary Q2 results, Lake Street analyst Chris Krueger tells investors in a research note. While the company continues to execute on its global lemon strategy, heavy rains in Southern California caused volatility in its core business, which should normalize in the coming quarters, adds the analyst. He remains confident Limoneira will continue to grow its core agribusiness and generate additional cash flow from its real estate and water rights. Krueger lowered his price target for the shares to $28 from $31 and keeps a Buy rating on Limoneira.
07/22/19
NATL
07/22/19
INITIATION
Target $30
NATL
Buy
Limoneira initiated with a Buy at National Securities
National Securities initiated Limonera with a Buy and $30 price target.
11/04/19
STFL
11/04/19
NO CHANGE
STFL
Limoneira directly-owned acres likely missed by CA wildfire, says Stifel
Stifel analyst Vincent Anderson said that based on local news reports of last week's wildfire outside Santa Paula, California, which is in close proximity to Limoneira's headquarters and packing facility, he believes most of the company's directly-owned acres in the vicinity likely avoided damage. However, he is "less certain" regarding whether any of the company's third-party growers' fruit was affected. Anderson has a Buy rating on Limoneira shares.
MCK McKesson
$143.62

-0.27 (-0.19%)

01/10/20
MSCO
01/10/20
UPGRADE
Target $162
MSCO
Overweight
Morgan Stanley upgrades McKesson, names Centene, Anthem top Healthcare picks
As previously reported, Morgan Stanley analyst Ricky Goldwasser upgraded McKesson (MCK) to Overweight from Equal Weight with a price target of $162, up from $135. Shares have underperformed the S&P in the last five years because of "a myriad of headwinds, with the most recent being concerns about opioids liability and its 2020/21 earnings power. However, Goldwasser believes specialty business and cost cutting initiatives can support earnings growth and exiting the investment in Change Healthcare (CHNG) should further strengthen McKesson's balance sheet, she tells investors. Her top picks in Healthcare Services for 2020 are Anthem (ANTM) and Centene (CNC). She sees the most multiple expansion opportunity for Anthem as it continues taking Medicare Advantage share and for Centene given its Wellcare (WCG) deal, said Goldwasser, who has a price targets of $382 for Anthem and $82 for Centene shares.
01/10/20
GUGG
01/10/20
NO CHANGE
Target $20
GUGG
Buy
Change Healthcare price target raised to $20 from $17 at Guggenheim
Guggenheim analyst Glen Santangelo believes Change Healthcare (CHNG) shares are only up 20% since the company's IPO due to overhangs that included a relatively new management team to the public markets, an FY20 business transition and potential selling pressure from the eventual exit of McKesson (MCK). However, noting that McKesson recently announced that it could complete its exit as early as March, he recommends buying on any weakness throughout 1Q as Santangelo believes the exit removes a key overhang. The analyst, who also believes the other overhangs will have a less meaningful impact going forward and expects investor expectations to quickly shift to the "achievable" consensus expectations for FY20 and FY21, raised his price target on Change Healthcare shares to $20 and keeps a Buy rating on the stock.
01/10/20
01/10/20
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrade with this list compiled by The Fly: 1. Qorvo (QRVO) and Skyworks (SWKS) upgraded to Buy from Neutral at Mizuho. 2. McKesson (MCK) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Ricky Goldwasser saying shares have underperformed the S&P in the last five years because of "a myriad of headwinds, with the most recent being concerns about opioids liability and its 2020/21 earnings power. 3. Edwards Lifesciences (EW) upgraded to Outperform from Perform at Oppenheimer. 4. Square (SQ) upgraded to Overweight from Equal Weight at Stephens with analyst Brett Huff saying he expects the company to beat revenue expectations and meet EBITDA expectations when it reports Q4 results. 5. L Brands (LB) upgraded to Buy from Hold at Deutsche Bank with analyst Tiffany Kanaga saying yesterday's holiday report, with Victoria's Secret reporting sales well below expectations, likely tips the scale "more toward a split, likely triggering strategic action in the near-term." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/20
MSCO
01/10/20
UPGRADE
Target $162
MSCO
Overweight
McKesson upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser upgraded McKesson to Overweight from Equal Weight with a $162 price target.
RTIX RTI Surgical
$2.76

0.1 (3.76%)

05/29/19
CANT
05/29/19
INITIATION
Target $7
CANT
Overweight
Cantor starts RTI Surgical at Overweight, sees valuation 'disconnect'
Cantor Fitzgerald analyst Craig Bijou initiated coverage of RTI Surgical Holdings with an Overweight rating and $7 price target. New management over the last two years has transitioned the company focus to higher growth novel therapies in spine through several acquisitions and licensing deals, Bijou tells investors in a research note. The analyst believes RTI's "new differentiated" spine products will become the "growth engine" for the company, supported by its "profitable" OEM business. He sees a "disconnect" between RTI's current valuation given the potential for growth in its spine business.
05/29/19
CANT
05/29/19
INITIATION
Target $7
CANT
Overweight
RTI Surgical initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou started RTI Surgical Holdings with an Overweight rating and $7 price target.
09/16/19
SIDC
09/16/19
INITIATION
Target $5
SIDC
Buy
RTI Surgical initiated with a Buy at Sidoti
Sidoti initiated RTI Surgical with a Buy and $5 price target.
LJPC La Jolla
$7.02

1.02 (17.00%)

11/26/19
HCWC
11/26/19
DOWNGRADE
HCWC
Neutral
La Jolla downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded La Jolla Pharmaceutical to Neutral from Buy without a price target. The analyst cites the discontinuation of the company's pipeline product LJPC-401 and the "sudden departure" of its CEO for the downgrade. White says he's "not comfortable" at this point to determine a price target given the perceived lack of clarity at La Jolla.
01/09/20
HCWC
01/09/20
NO CHANGE
HCWC
H.C. Wainwright still sees 2020 sales of La Jolla's Giaprezza as immaterial
H.C. Wainwright analyst Edward White maintained a Neutral rating on La Jolla following the company's preannouncement of Q4 and FY19 Giapreza sales, which were $7.2M and $23.1M, respectively. While the sales were higher than the analyst had forecast, he continues to believe they will be immaterial in 2020, and maintained a Neutral rating due to the company's discontinuation of its pipeline product LJPC-401 and sudden departure of its CEO.
11/25/19
RHCO
11/25/19
DOWNGRADE
RHCO
Hold
La Jolla downgraded to Hold from Buy at SunTrust
SunTrust downgraded La Jolla to Hold from Buy.
11/26/19
NOMU
11/26/19
NO CHANGE
Target $29
NOMU
Buy
La Jolla failure a positive for Protagonist Therapeutics, says Nomura Instinet
La Jolla Pharmaceutical (LJPC), a Protagonist Therapeutics (PTGX) competitor, announced yesterday that it will reassess development of LJPC-401, its synthetic human hepcidin formulation, due to mixed clinical results, Nomura Instinet analyst Christopher Marai tells investors in a research note. The analyst views the news positively for Protagonist's competing drug, PTG-300. He keeps a Buy rating on Protagonist shares with a $29 price target.
ZUMZ Zumiez
$33.02

-0.78 (-2.31%)

11/26/19
JEFF
11/26/19
NO CHANGE
Target $38
JEFF
Buy
Zumiez price target raised to $38 from $34 at Jefferies
Jefferies analyst Janine Stichter said she finds that many of the larger retro and streetwear brands are seeing search interest track flat to down with weakened social media engagement, which she views as a signal that the the cycle is now past peak, although the category is still broadly healthy. Even with a fairly heavy reliance on Vans, Zumiez (ZUMZ) is sufficiently diverse to weather a deceleration in the retro cycle and data also suggests a major resurgence in skateboards, which is positive for Zumiez, said Stichter, who raised her price target on the stock to $38 from $34 and keeps a Buy rating on the shares. Despite the broader downtrend in the retro brand cycle, he checks also indicate that the Guess (GES) brand is "in the earlier stages of capitalizing on its status as a retro 90s brand," added Stichter.
09/09/19
BARD
09/09/19
NO CHANGE
Target $33
BARD
Neutral
Zumiez removed as Fresh Pick at Baird
Baird analyst Jonathan Komp removed the Fresh Pick from Zumiez following its recent gain. The analyst said he continues to see upside potential to near-term estimates amid solid comps momentum and conservative second half projections. Komp maintained his Neutral rating and $33 price target on Zumiez shares.
09/06/19
DADA
09/06/19
NO CHANGE
Target $28
DADA
Neutral
Zumiez price target raised to $28 from $20 at DA Davidson
DA Davidson analyst John Morris raised his price target on Zumiez to $28 after its Q2 earnings beat, saying the company's footwear and hardgoods drove the sales growth. The analyst adds that the company saw "notable" strength in its European market, which contributed to its positive comps, but keeps his Neutral rating, citing limited visibility on how Zumiez will handle its tariff exposure and improve performance in the apparel category.
12/06/19
DADA
12/06/19
NO CHANGE
Target $33
DADA
Neutral
Zumiez price target raised to $33 from $28 at DA Davidson
DA Davidson analyst John Morris raised his price target on Zumiez to $33 after its "strong" Q3 revenue growth and margin expansion, with the management noting strength in its footwear and hardgoods categories offset by mens and womens category weakness. The analyst still keeps his Neutral rating however, noting he prefers to see improvement and positive comps across those segments in order to become more constructive on the stock.
MMSI Merit Medical
$34.66

-0.03 (-0.09%)

10/31/19
BRRR
10/31/19
NO CHANGE
Target $31
BRRR
Outperform
Merit Medical price target lowered to $31 from $59 at Barrington
Barrington analyst Michael Petusky lowered his price target for Merit Medical Systems to $31 from $59 saying the company's profitability in Q3 fell well short and its guidance was reduced significantly. Merit's "somewhat disappointing" revenue growth rate was less to blame for the quarter's profitability miss than the company's lack of discipline regarding operating expenses, Petusky tells investors in a post-earnings research note. He keeps an Outperform rating on the shares.
12/12/19
WELS
12/12/19
DOWNGRADE
WELS
Underweight
SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen double-downgraded Glaukos (GKOS) and SeaSpine (SPNE) to Underweight from Overweight as part of his broader Medical Technology industry research note. The analyst expects the medical device sector to be part of the "politics of healthcare" storm heading into next year's elections given the focus on drug pricing and increasing access to healthcare, even though he sees the broader risks as "manageable" for another year with "medtech tax" likely to be suspended. Biegelsen also cuts his rating on Merit Medical (MMSI) to Underweight from Equal Weight, but offers a positive view on Medtronic (MDT), citing its accelerating growth story trading at a discount relative to peer valuation and sees Teleflex (TFX) as "among the best positioned" in his coverage with UroLift as its key growth accelerator.
12/12/19
WELS
12/12/19
DOWNGRADE
Target $26
WELS
Underweight
Merit Medical downgraded to Underweight from Equal Weight at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen downgraded Merit Medical Systems to Underweight from Equal Weight with a $26 price target as part of his broader Medical Technology industry research note. Biegelsen cites the challenging trends coming out of 2019 and a lack of visibility going forward after the company pulled its 2020 guidance for the downgrade. Biegelsen tells investors that he believes what came to light in 2019 was Merit's prioritization of top line growth along with multiple acquisition integrations at the expense of earnings growth.
12/12/19
WELS
12/12/19
DOWNGRADE
Target $26
WELS
Underweight
Merit Medical downgraded to Underweight from Equal Weight at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen downgraded Merit Medical Systems to Underweight from Equal Weight with a $26 price target.
WYNN Wynn Resorts
$147.23

4.22 (2.95%)

01/13/20
GSCO
01/13/20
UPGRADE
Target $181
GSCO
Conviction Buy
Wynn Resorts upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Grambling added Wynn Resorts (WYNN) to the America's Conviction List and kept a Buy rating on the stock with a price target of $181, up from $157. The analyst is positive on Wynn due to a more bullish outlook on Macau, with "negative trends in Macau turning positive and leading indicators in both Las Vegas and Macau strengthening." The analyst also said trade tensions between the U.S. and China have eased, and noted that positive policy initiatives for Macau were announced by President Xi. Grambling also remained Buy rated on Las Vegas Sands (LVS) and Red Rock Resorts (RRR).
12/24/19
MSCO
12/24/19
NO CHANGE
MSCO
Morgan Stanley sees positive read to Boyd and peers from DraftKings' valuation
After DraftKings announced yesterday that it is being bought by Special Purpose Acquisition Company Diamond Eagle (DEAC) and merging with SBTech in a deal that values the combined U.S. sports betting pure play company at an enterprise value of $2.7B, Morgan Stanley analyst Thomas Allen said he sees this new valuation as having a positive read-through for Boyd Gaming (BYD), Eldorado Resorts (ERI) and Penn National (PENN), which he thinks are likely to also be meaningful long-term beneficiaries from U.S. sports betting. He also sees the read-through being positive for MGM Resorts (MGM) and Wynn Resorts (WYNN), though to a lesser extent given the scale of those two.
01/10/20
WOLF
01/10/20
UPGRADE
Target $176
WOLF
Outperform
Wynn Resorts upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Wynn Resorts to Outperform from Peer Perform with a $176 price target.
01/08/20
SBSH
01/08/20
DOWNGRADE
SBSH
Neutral
Wynn Resorts downgraded to Neutral from Buy at Citi
Citi downgraded Wynn Resorts to Neutral from Buy.
ACIW ACI Worldwide
$39.08

0.58 (1.51%)

11/12/19
SPHN
11/12/19
NO CHANGE
Target $38
SPHN
Overweight
ACI Worldwide CEO exit makes buyout more likely, says Stephens
Stephens analyst Brett Huff said ACI Worldwide does not get credit for greater than 25% SpeedPay accretion, which he believes is due to two big delayed renewals and poor year-to-date bookings. However, he thinks renewing one big deal that had been delayed muted the one worry and that anemic bookings are likely a timing issue. He also points to a "new" reason to own the stock, namely his view that the retirement of CEO Phil Heasley makes a potential buyout more likely. The analyst, who estimates a theoretical buyout price of about $44 per share, reiterates an Overweight rating and $38 price target on ACI Worldwide shares.
12/19/19
ADAM
12/19/19
INITIATION
Target $44
ADAM
Buy
ACI Worldwide initiated with a Buy at Canaccord
Earlier, Canaccord analyst Joseph Vafi initiated coverage of ACI Worldwide with a Buy rating and $44 price target.
09/12/19
09/12/19
INITIATION
Target $40

Buy
ACI Worldwide initiated with a Buy at BTIG
As previously reported, BTIG analyst Mark Palmer initiated ACI Worldwide with a Buy and $40 price target. The analyst cites the findings of his sum-of-the-parts analysis of the company's On Premise and On Demand segments, stating that the stock has become "overlooked and underfollowed". Palmer adds that delays in deals with payment giants has been the source of the recent weakness in ACI Worldwide stock price, but he expects those issues to be "favorably resolved".
11/20/19
SPHN
11/20/19
NO CHANGE
Target $41
SPHN
Overweight
ACI Worldwide price target raised to $41 after analyst day at Stephens
Stephens analyst Brett Huff raised his price target on ACI Worldwide shares to $41 from $38 following the company's analyst day meeting, during which he thinks the company did a good job showing that the SpeedPay asset is a higher-quality business than many believed. He also said the company did a good job "reminding the market of just how well positioned it is to win in the real-time payments market." Huff keeps an Overweight rating on ACI Worldwide shares.
GME GameStop
$5.44

0.005 (0.09%)

01/07/20
BOFA
01/07/20
NO CHANGE
Target $85
BOFA
Buy
Aaron's, Lowe's positioned for outperformance in 2020, says BofA
In a research note on retailers, BofA analyst Elizabeth Suzuki said she thinks the stocks that are best positioned for outperformance in 2020 are Aaron's (AAN), Advance Auto Parts (AAP), Bed Bath & Beyond (BBBY), Lowe's (LOW) and Tempur Sealy (TPX). Conversely, the analyst thinks several hardline retail stocks are poised to underperform in 2020, including Floor & Decor (FND), GameStop (GME), Michael's (MIK) and Sleep Number (SNBR). The firm's proprietary RENO barometer suggests that renovation spending may sequentially improve through 1H before tapering off in 2H. While she nots that essentially every company in her coverage universe stands to gain from a trade war resolution, the biggest beneficiaries would likely be Michael's, Floor & Decor, Best Buy (BBY), RH (RH) and Williams-Sonoma (WSM). Suzuki raised her price target for Aaron's to $85 from $80.
10/22/19
10/22/19
NO CHANGE

GameStop management to meet with Jefferies
Meeting to be held in New York on October 23 hosted by Jefferies.
09/12/19
LOOP
09/12/19
NO CHANGE
Target $4
LOOP
Hold
Loop Capital sees 'steep uphill' for recovery at GameStop
Loop Capital analyst Anthony Chukumba kept his Hold rating and $4 price target on GameStop, saying its below-consensus Q2 earnings and a cut in FY19 guidance offers "no compelling reason" to become more constructive on the stock. The analyst believes that the new management still has a "steep uphill" to turn around the company's performance and expects the company to struggle until the next video game cycle begins in late 2020, with no assurances that it will cure its "current ills".
12/11/19
BARD
12/11/19
NO CHANGE
Target $5
BARD
Neutral
Baird cuts GameStop price target to $5 after 'double whammy' Q3
Baird analyst Colin Sebastian lowered his price target for GameStop to $5 from $6 and keeps a Neutral rating on the shares. The company's Q3 report included the "double whammy" of an end-of-cycle downturn and broader shift digital, Sebastian tells investors in a post-earnings research note. GameStop reported results below consensus expectations, driven by accelerating declines in new hardware and software sales, says the analyst. He believes the company's early signs of progress on its strategic initiatives will likely continue to be overshadowed by "significant industry-wide headwinds" for new product sales ahead of next year's console refresh, as well as the broader digital shift.
ETH Ethan Allen
$17.86

0.25 (1.42%)

02/04/19
RAJA
02/04/19
DOWNGRADE
RAJA
Market Perform
Ethan Allen downgraded to Market Perform from Outperform at Raymond James
01/29/19
DOTC
01/29/19
DOWNGRADE
DOTC
Neutral
Ethan Allen downgraded to Neutral from Buy at Dougherty
02/04/19
02/04/19
DOWNGRADE

Market Perform
Ethan Allen downgraded to Market Perform at Raymond James
As previously reported, Raymond James downgraded Ethan Allen to Market Perform from Outperform following the Q2 report and conference call. Analyst Bobby Griffin said sales growth remains "elusive" and will look for further detail on the forward growth strategy at Ethan Allen's upcoming investor day.
STML Stemline
$9.42

-0.38 (-3.88%)

08/06/19
PIPR
08/06/19
NO CHANGE
Target $25
PIPR
Overweight
NTAP suggests 'significant upside' to Stemline model assumptions, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that Stemline was granted approval for a new technology add-on payment for Elzonris, which allows for additional reimbursement for Medicare patients beyond the DRG-based payment. While notable, within the CMS decision is further detail around Elzonris dosing that could have "significant positive" implications to his model assumptions. Mainly, the analyst may be under-modeling the number of vials per dose and pricing per newly diagnosed patient may be 90% more than he was modeling. Catanzaro reiterates an Overweight rating and $25 price target on the shares.
12/24/19
CANT
12/24/19
INITIATION
Target $18
CANT
Overweight
Stemline initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young initiated coverage of Stemline Therapeutics with an Overweight rating and $18 price target.
12/24/19
12/24/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Hold from Buy at Argus with analyst John Eade saying while the stock has underperformed the market and its peer group he has "low confidence" that the company's earnings power can recover in the near term as its core FedEx Express revenues and margins are sliding. 2. AquaVenture (WAAS) was downgraded to Neutral from Buy at B. Riley FBR, to Hold from Buy at Lake Street, to Sector Perform from Outperform at RBC Capital, and to Market Perform from Outperform at Raymond James. The downgrades came after the company announced yesterday that it has agreed to be acquired by Culligan for $27.10 per share in cash. 3. MannKind (MNKD) initiated with an Outperform rating and $2.50 price target at Oppenheimer. 4. Amgen (AMGN) and Regeneron (REGN) were initiated with a Market Perform at Raymond James. 5. Stemline (STML) initiated with an Overweight rating at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/24/19
CANT
12/24/19
INITIATION
Target $18
CANT
Overweight
Cantor sees 'pipeline in a product' for Stemline, starts with Overweight rating
Cantor Fitzgerald analyst Alethia Young initiated coverage of Stemline Therapeutics with an Overweight rating and $18 price target. The stock closed Monday up 28c to $10.77. Elzonris could be a "pipeline in a product" for Stemline, which is underappreciated by investors, Young tells investors in a research note. Stemline has a current market capitalization of $520M, and the analyst expects sales from Elzonris for blastic plasmacytoid dendritic cell neoplasm, excluding maintenance therapy, in the U.S. alone to be over $150M by 2025. In addition, Young thinks the potential expansion of Elzonris into the BPDCN maintenance setting in 2021 could produce unadjusted peak U.S. sales of $223M in 2029. She sees upside in the shares over the next 12 months "as investors take notice of progress in the label expansion opportunities."
STAG STAG Industrial
$31.98

0.26 (0.82%)

12/18/19
JPMS
12/18/19
NO CHANGE
JPMS
JPMorgan makes 17 REIT rating changes in conjunction with 2020 outlook
JPMorgan analysts Anthony Paolone and Michael Mueller made 17 rating changes in conjunction with their 2020 real estate investment trust outlook. The upgrades to Overweight from Neutral are Alexandria Real Estate (ARE), AvalonBay (AVB), Brixmor (BRX), Americold Realty Trust (COLD), EPR Properties (EPR), Healthcare Trust (HTA) and STAG Industrial (STAG). The upgrade to Neutral from Underweight is Macerich (MAC). The downgrades to Neutral from Overweight are Boston Properties (BXP), Equity Residential (EQR), Kimco Realty (KIM), Regency Centers (REG), Simon Property (SPG) and Welltower (WELL). The downgrades to Underweight from Neutral are Mack-Cali Realty (CLI), Monmouth Real Estate (MNR) and Taubman Centers (TCO). The analysts note that JPMorgan's rating system is a relative system tied to coverage universe that utilizes the whole ratings spectrum.
12/18/19
12/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delta Air Lines (DAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying airline stocks are discounting risk from Boeing's (BA) 737 MAX. 2. Eli Lilly (LLY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying Lilly offers "strong" earnings growth potential and "significant" pipeline optionality from its base as the smallest U.S. Major Pharma with the lowest margins. 3. Sasol (SSL) upgraded to Buy from Neutral at BofA/Merrill. 4. STAG Industrial (STAG) upgraded to Overweight from Neutral at JPMorgan and to Top Pick from Outperform at RBC Capital. 5. Sabra Health Care (SBRA) upgraded to Neutral from Sell at Citi with analyst Nicholas Joseph saying while the skilled nursing environment remains challenged, 2020 earnings growth is now closer to healthcare REIT peers and Sabra's valuation is fairer following the recent underperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/20
RAJA
01/07/20
NO CHANGE
RAJA
Industrial REIT sector upgraded to Overweight at Raymond James
Raymond James analyst William Crow upgraded his rating on the Industrial REIT sector to Overweight from Market Weight. The analyst added STAG Industrial to his Top Picks list.
12/18/19
RBCM
12/18/19
UPGRADE
Target $34
RBCM
Top Pick
STAG Industrial upgraded to Top Pick from Outperform at RBC Capital
RBC Capital analyst Michael Carroll upgraded STAG Industrial to Top Pick from Outperform with a price target of $34, up from $33. The analyst expects the company's same-store net operating income to continue trending higher in 2020 as its management projects growth of 2%-3% over the next 3-5 years, citing STAG Industrial's "strengthening market" as well as its more formalized process in "enlisting 3rd party brokers to negotiate renewals".

TODAY'S FREE FLY STORIES

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.